RxDoctor Payments Data

Ninfa Recinto

Acute Care · Cherry Hill, NJNPI 1760968382

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Vifor Pharma, Inc. accounts for 71.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $2,909 and has fallen 93.4% since, to $192 in 2025. Among acute care clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,417in general payments, 2019–2025

Across 36 payments — averaging $122.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$3K
  • Fresenius USA Marketing, Inc.$278
  • Ardelyx, Inc.$275
  • Bayer$236
  • Calliditas Therapeutics US Inc.$137
  • Akebia Therapeutics Inc$136
  • plus $221 from 4 others

What the payments were for

  • Consulting fees$81018%
  • Travel & lodging$1,47933%
  • Food & beverage$2,12848%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,417 in reported general payments places this provider in the 90th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Medicare billing

Part B allowed, 2024
$21,426
Medicare patients
71
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl22$83,121
VelphoroSucroferric Oxyhydroxide12$69,111
Sevelamer Carbonate64$9,927
ProsolParenteral Amino Acid 20% No.131$4,250
Midodrine Hcl21$555
Hydralazine Hcl30$294
Atorvastatin Calcium16$173
Carvedilol19$89
Clonidine Hcl16$77
Amlodipine Besylate18$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$278$69,11112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 656 acute care providers in New Jersey.

Other acute care in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →